NCT00496431 2022-01-27phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma PatientsItalfarmacoPhase 1/2 Terminated19 enrolled
NCT00792831 2022-01-27Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic LeukemiaItalfarmacoPhase 2 Terminated3 enrolled